Trillium Therapeutics Inc. | Key People and Executives
Niclas Stiernholm
President, Chief Executive Officer & Director
Henry Friesen
Director-Emeritus
Helena Katrina Tayton-Martin
Director
Calvin R. Stiller
Chairman
Thomas C. Reynolds
Independent Director
Luke M. Beshar
Independent Director
Michael G. Moore
Independent Director
Robert L. Kirkman
Independent Director
Niclas Stiernholm
President, Chief Executive Officer & Director
James T. Parsons
Chief Financial Officer & Secretary
Yaping Shou
Chief Medical Officer
Robert A. Uger
Chief Scientific Officer
Brian Jahns
Senior VP-Commercial & Business Development
Malik Slassi
Senior Vice President-Discovery Research
Penka Petrova
Chief Development Officer
Henry Friesen
Director-Emeritus
Helena Katrina Tayton-Martin
Director
Calvin R. Stiller
Chairman
Thomas C. Reynolds
Independent Director
Luke M. Beshar
Independent Director
Michael G. Moore
Independent Director
Robert L. Kirkman
Independent Director
| Address |
2488 Dunwin Drive
Mississauga Ontario L5L 1J9
Canada
|
|
Employees
|
- |
| Website |
http://www.trilliumtherapeutics.com |
| Updated |
07/08/2019 |
| Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada. |
